欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Pemetrexed Pfizer (previously Pemetrexed Hospira UK Limited)
适用类别Human
治疗领域Carcinoma, Non-Small-Cell Lung;Mesothelioma
通用名/非专利名称pemetrexed
活性成分pemetrexed ditromethamine
产品号EMEA/H/C/004488
患者安全信息No
许可状态Withdrawn
ATC编码L01BA04
是否额外监管No
是否仿制药或hybrid药物Yes
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2017/04/24
上市许可开发者/申请人/持有人Pfizer Europe MA EEIG
人用药物治疗学分组ANTIMETABOLITES;Folic acid analogues
兽用药物治疗学分组
审评意见日期2017/02/23
欧盟委员会决定日期2020/10/21
修订号7
治疗适应症Malignant pleural mesothelioma Pemetrexed Hospira UK Limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed Hospira UK Limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1). Pemetrexed Hospira UK Limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see SmPC section 5.1). Pemetrexed Hospira UK Limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1).
适用物种
兽用药物ATC编码
首次发布日期2018/04/24
最后更新日期2021/07/29
产品说明书https://www.ema.europa.eu/en/documents/product-information/pemetrexed-pfizer-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/pemetrexed-pfizer-previously-pemetrexed-hospira-uk-limited
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase